Terminal β-galactose–containing N-linked glycans (Gal-N-glycans)

Terminal β-galactose–containing N-linked glycans are complex carbohydrate structures covalently attached to the asparagine residues of proteins, characterized by a galactose sugar at the non-reducing end. These glycans play a fundamental role in determining the circulatory half-life of glycoproteins, as they are the primary ligands for the asialoglycoprotein receptor (ASGPR) in the liver, which mediates their endocytosis and degradation. In the context of immunology, the degree of terminal galactosylation on the Fc region of IgG antibodies significantly influences effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Pathologically, altered galactosylation patterns are hallmark features of chronic inflammatory conditions like rheumatoid arthritis and are frequently exploited by cancer cells to facilitate metastasis and immune evasion through interactions with galectins. Therapeutic strategies involving these glycans include glycoengineering of monoclonal antibodies to optimize pharmacokinetics and the development of galectin inhibitors to disrupt pro-tumorigenic glycan-protein interactions. Furthermore, certain pathogens, including specific adeno-associated virus (AAV) serotypes, utilize these terminal galactose residues as essential cell-surface receptors for host entry.

Other names

Galactosylated N-glycansAsialo-N-linked glycansTerminal β-galactosyl N-linked oligosaccharidesG1/G2 glycoformsComplex N-glycans with terminal galactose

Binding to carbohydrate-recognition domains (CRDs) of galectins or asialoglycoprotein receptors (ASGPR) to modulate cellular signaling, endocytosis, or immune responses.